ExActa HIF prolyl hydroxylase inhibitors—The new lifestyle drug?-Reference-Cited by-同舟云学术

ExActa HIF prolyl hydroxylase inhibitors—The new lifestyle drug?

Published:2019-09-17 Issue:3 Volume:227 Page:
ISSN:1748-1708
Container-title:Acta Physiologica
language:en
Short-container-title:Acta Physiol

Author:

Sciesielski Lina K.¹,Kirschner Karin M.²

Affiliation:

1. Charité – Universitätsmedizin Berlin, corporate member of Freie Universität BerlinHumboldt‐Universität zu Berlin, and Berlin Institute of HealthDepartment of Neonatology Berlin Germany

2. Charité – Universitätsmedizin Berlin, corporate member of Freie Universität BerlinHumboldt‐Universität zu Berlin, and Berlin Institute of HealthInstitute of Vegetative Physiology Berlin Germany

Publisher

Wiley

Subject

Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apha.13370

Reference28 articles.

1. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism

2. Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis

3. Roxadustat: First Global Approval

4. Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases

5. The human oxygen sensing machinery and its manipulation

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Erythropoietin‐producing cells in the kidney: Novel insights in their long‐term fate during hypoxaemia and renal tissue remodelling;Acta Physiologica;2022-01-19

2. A validated method for the quantification of IOX‐2, a potent prolyl hydroxylase inhibitor in equine urine and plasma using liquid chromatography–high‐resolution mass spectrometry;Drug Testing and Analysis;2021-02-06

3. Pregnancy;Acta Physiologica;2020-12-13